1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline variables of patients and controls^{^a}
Natalizumab (n = 25) IFNb/GA (n = 18) Healthy Controls (n = 12) P Value
Age (yr) 36.0 ± 8.9 38.2 ± 5.0 37.6 ± 8.7 .619
Sex (male/female) 9:16 9:9 3:9 .368
EDSS^{^b,^c} 3.0 (1.5–6.5) 2.5 (1.0–6.5) .589
Duration since onset (yr) 7.9 ± 6.1 8.8 ± 5.3 .550
Prior IFNb/GA duration at baseline (yr) 2.6 ± 3.0 4.4 ± 3.9 .121
Brain volumes 
    NGMV (L) 0.75 ± 0.04 0.73 ± 0.05 0.77 ± 0.04 .063
    NWMV (L) 0.70 ± 0.03 0.69 ± 0.03 0.72 ± 0.04 .061
    NBV (L) 1.45 ± 0.05 1.42 ± 0.08 1.49 ± 0.07 .020^{^d}
T2 lesion volume (mL)^{^e} 6.1 (2.4–14.3) 4.9 (2.4–11.9) .599
Note:—EDSS indicates Expanded Disability Status Scale; NGMV, normalized total GM volume; NWMV, normalized total WM volume; NBV, normalized whole-brain volume.
↵a Data are mean ± SD. When normally distributed, a multivariate general linear model was used with age and sex included as covariates. Nonparametric testing was performed using Kruskal-Wallis and post hoc Mann-Whitney U tests.
↵b χ² test.
↵c Median and range.
↵d Only significant between patients treated with IFNb/GA and healthy controls.
↵e Median and interquartile range.